Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.

Montagner, Isabella Monia; Merlo, Anna; Carpanese, Debora; Zuccolotto, Gaia; Renier, Davide; Campisi, Monica; Pasut, Gianfranco; Zanovello, Paola; Rosato, Antonio

Montagner, Isabella Monia; Merlo, Anna; Carpanese, Debora; Zuccolotto, Gaia; Renier, Davide; Campisi, Monica; Pasut, Gianfranco; Zanovello, Paola; Rosato, Antonio.

Afiliación

Montagner IM; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Merlo A; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Carpanese D; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Zuccolotto G; Department of Medicine, University of Padua, Padua, Italy.
Renier D; Fidia Farmaceutici S.p.A, Abano Terme, Italy.
Campisi M; Fidia Farmaceutici S.p.A, Abano Terme, Italy.
Pasut G; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Zanovello P; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy ; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Rosato A; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy ; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

Oncoscience ; 2(4): 373-81, 2015.

Article en En | MEDLINE | ID: mdl-26097871

Palabras clave

SN-38; bioconjugate; hyaluronan; ovarian cancer; tumor targeting

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Oncoscience Año: 2015 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google